๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Inducement of specific CTLs by antigen-peptides from human leukemia cells and their cytotoxicity to leukemia cells

โœ Scribed by Zuohua Feng; Guimei Zhang; Bo Huang; Dong Li; Hongtao Wang


Publisher
Springer-Verlag
Year
2002
Tongue
Chinese
Weight
458 KB
Volume
22
Category
Article
ISSN
0510-9752

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Murine leukemia cell hybrids: The quanti
โœ Cohen, Edward P. ;Liang, Weitze ๐Ÿ“‚ Article ๐Ÿ“… 1978 ๐Ÿ› Wiley (John Wiley & Sons) ๐ŸŒ English โš– 708 KB

## Abstract The quantity of thymusโ€leukemia (TL) antigens expressed by murine leukemia cells is significantly greater than that expressed by somatic hybrids of such cells. Based upon the results of ^125^Iโ€lactoperoxidase labeling and antibody absorption procedures, and corrected for size difference

Enhanced expression of human T-cell leuk
โœ Florry A. Vyth-Dreese; Jan E. De Vries ๐Ÿ“‚ Article ๐Ÿ“… 1983 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 847 KB

## Abstract Peripheral blood T cells from a patient with Tโ€cell chronic lymphocytic leukemia (Tโ€CLL) failed to respond to mitogenic lectins or alloantigens but could be induced to proliferate by the addition of exogenous interleukinโ€2 (ILโ€2). The Tโ€CLL cells also proliferated in response to 12โ€__O_

Inhibition of in vitro lymphoproliferati
โœ Moshe Glaser; Holger Kirchner; Ronald B. Herberman ๐Ÿ“‚ Article ๐Ÿ“… 1975 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 635 KB

## Abstract W/Fu rats were injected subcutaneously with low numbers of cells from the Gross leukemia virusโ€induced lymphoma, (C58NT) D, which induced transient tumor growth and regression (regressors), or with high numbers of tumor cells resulting in progressive tumor growth (progressors). Spleen c

Peptide-antibody conjugates for tumour t
โœ Zhiwei Yu; Frank Healy; Danila Valmori; Patricia Escobar; Giampietro Corradin; J ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 729 KB

Anti-idiotype antibody therapy of B-cell lymphomas, despite numerous promising experimental and clinical studies, has so far met with limited success. Tailor-made monoclonal antiidiotype antibodies have been injected into a large series of lymphoma patients, with a few impressive complete tumour rem